AF in CF-LVAD patients was not associated with overall TE , stroke , or device thrombosis events .
These findings might be explained by the highly thrombogenic property of CF-LVADs that exceeds the thromboembolic risk driven by AF
Atrial fibrillation ( AF ) is a well-established risk factor of thromboembolism ( TE ) .
Thromboembolism is one of the most common complications in patients supported by continuous-flow left ventricular assisted devices ( CF-LVADs ) .
However , the association between AF and TE complications in this population is controversial .
We conducted a systematic review and meta- analysis to assess the association between AF and overall TE , stroke , and device thrombosis events in CF-LVAD patients .
HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial.
BACKGROUND The HeartWare Ventricular Assist System ( HeartWare Inc , Framingmam , MA ) is a miniaturized implantable , centrifugal design , continuous-flow blood pump . The pivotal bridge to transplant and continued access protocol s trials have enrolled patients with advanced heart failure in a bridge-to-transplant indication . METHODS The primary outcome , success , was defined as survival on the originally implanted device , transplant , or explant for ventricular recovery at 180 days . Secondary outcomes included an evaluation of survival , functional and quality of life outcomes , and adverse events . RESULTS A total of 332 patients in the pivotal bridge to transplant and continued access protocol s trial have completed their 180-day primary end-point assessment . Survival in patients receiving the HeartWare pump was 91 % at 180 days and 84 % at 360 days . Quality of life scores improved significantly , and adverse event rates remain low . CONCLUSIONS The use of the HeartWare pump as a bridge to transplant continues to demonstrate a high 180-day survival rate despite a low rate of transplant . Adverse event rates are similar or better than those observed in historical bridge-to-transplant trials , despite longer exposure times due to longer survival and lower transplant rates
AF in CF-LVAD patients was not associated with overall TE , stroke , or device thrombosis events .
These findings might be explained by the highly thrombogenic property of CF-LVADs that exceeds the thromboembolic risk driven by AF
Atrial fibrillation ( AF ) is a well-established risk factor of thromboembolism ( TE ) .
Thromboembolism is one of the most common complications in patients supported by continuous-flow left ventricular assisted devices ( CF-LVADs ) .
However , the association between AF and TE complications in this population is controversial .
We conducted a systematic review and meta- analysis to assess the association between AF and overall TE , stroke , and device thrombosis events in CF-LVAD patients .